ResMed Inc. (RMD)

NYQ – Real vaqt narxi. Valyuta: USD

200.29

+1.69 (0.85%)

Yopilishda: Jun 26, 2026, 4:00 PM EDT

201.00

+0.71 (0.35%)

Bozordan keyin: Jun 26, 2026, 7:56 PM EDT

17.06.2026

Here Are Wednesday's Best Wall Street Analyst Research Calls: Block, Charles River Laboratories, Cognizant Technology, Constellation Energy, Credicorp, First Solar, GE Vernova, Huntsman, Macerich, and More

Futures are trading mixed as we hit the midweek point, as the Space Exploration Technologies (NASDAQ: SPCX) or SpaceX IPO rush is starting to fade somewhat.

16.06.2026

Why ResMed (RMD) is a Top Growth Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

11.06.2026

ResMed: GLP-1 Threats Are Overstated

My contrarian take on ResMed is that GLP-1 concerns are overstated, and even though a portion of market share will be lost, the remaining portion will be more beneficial to profitability. Other business threats come from PHG's reentrance and Apnimed's drug commercialization. While not to be overlooked, I still see RMD retaining its market dominance. The stock currently trades as if revenues are already declining and margins are contracting. But the opposite is true. Margins far exceed peers, and the top line grows at double digits.

09.06.2026

Is This the Right Time to Retain Resmed Stock in Your Portfolio?

RMD gains from acquisition-led Residential Care Software growth, mask innovation and strong finances but faces macro and competitive pressures.

08.06.2026

Top 50 High-Quality Dividend Growth Stocks For June 2026

I track a curated universe of 50 high-quality dividend growth stocks to identify attractive entry points based on valuation and forward return potential. Year-to-date, the universe lags SPY and SCHD, but select names like LRCX (+343%) and KLAC (+208%) have dramatically outperformed since inception. Currently, 40 stocks offer forward return estimates of at least 10%, with 24 appearing potentially undervalued by my free cash flow model.

03.06.2026

Angelini Ventures Marks First Portfolio Company Exit as ResMed Acquires Noctrix Health for $340 million

Angelini Ventures marks its first portfolio exit as ResMed acquires Noctrix Health, validating its strategy of backing breakthrough healthcare innovation.

03.06.2026

ResMed Inc. (RMD) Presents at 46th Annual William Blair Growth Stock Conference Prepared Remarks Transcript

Videolar

No Data

There is no data to display

Press-relizlar

03.06.2026

Angelini Ventures Marks First Portfolio Company Exit as ResMed Acquires Noctrix Health for $340 million

Angelini Ventures marks its first portfolio exit as ResMed acquires Noctrix Health, validating its strategy of backing breakthrough healthcare innovation.

01.06.2026

Resmed Completes Acquisition of Noctrix Health, Expanding Clinical Sleep Health Portfolio

Acquisition adds Nidra® Tonic Motor Activation (TOMAC) Therapy, an FDA De Novo classified, nonpharmacologic treatment designed to address moderate-to-severe Restless Legs Syndrome (RLS). Acquisition adds Nidra® Tonic Motor Activation (TOMAC) Therapy, an FDA De Novo classified, nonpharmacologic treatment designed to address moderate-to-severe Restless Legs Syndrome (RLS).

19.05.2026

Resmed Announces Participation in the 46th Annual William Blair Growth Stock Conference

SAN DIEGO, May 19, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chairman and chief executive officer, and Aaron Bloomer, chief financial officer, will attend the 46th Annual William Blair Growth Stock Conference in Chicago, IL on Tuesday, June 2, 2026. Resmed's webcast presentation will begin at approximately 4:40 p.m. (Central Time).

19.05.2026

Resmed and ŌURA Partner to Expand Access to Sleep Health Education and Care

SAN DIEGO, May 19, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, and ŌURA, maker of the world's leading smart ring, today announced they are partnering to expand access to sleep health education and pathways to care, helping more people sleep better and improve their overall health. Sleep is increasingly recognized as a key pillar of long-term health, yet it remains widely underprioritized.1 Early signs of poor sleep are often dismissed, creating a gap between what people experience and when they seek support or clinical care.

ResMed Inc. (RMD)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

ResMed Inc. (RMD)

Here Are Wednesday's Best Wall Street Analyst Research Calls: Block, Charles River Laboratories, Cognizant Technology, Constellation Energy, Credicorp, First Solar, GE Vernova, Huntsman, Macerich, and More

Why ResMed (RMD) is a Top Growth Stock for the Long-Term

ResMed: GLP-1 Threats Are Overstated

Is This the Right Time to Retain Resmed Stock in Your Portfolio?

Top 50 High-Quality Dividend Growth Stocks For June 2026

Angelini Ventures Marks First Portfolio Company Exit as ResMed Acquires Noctrix Health for $340 million

ResMed Inc. (RMD) Presents at 46th Annual William Blair Growth Stock Conference Prepared Remarks Transcript

Videolar

No Data

Press-relizlar

Angelini Ventures Marks First Portfolio Company Exit as ResMed Acquires Noctrix Health for $340 million

Resmed Completes Acquisition of Noctrix Health, Expanding Clinical Sleep Health Portfolio

Resmed Announces Participation in the 46th Annual William Blair Growth Stock Conference

Resmed and ŌURA Partner to Expand Access to Sleep Health Education and Care

Here Are Wednesday's Best Wall Street Analyst Research Calls: Block, Charles River Laboratories, Cognizant Technology, Constellation Energy, Credicorp, First Solar, GE Vernova, Huntsman, Macerich, and More

Why ResMed (RMD) is a Top Growth Stock for the Long-Term

ResMed: GLP-1 Threats Are Overstated

Is This the Right Time to Retain Resmed Stock in Your Portfolio?

Top 50 High-Quality Dividend Growth Stocks For June 2026

Angelini Ventures Marks First Portfolio Company Exit as ResMed Acquires Noctrix Health for $340 million

ResMed Inc. (RMD) Presents at 46th Annual William Blair Growth Stock Conference Prepared Remarks Transcript

Videolar

No Data

Press-relizlar

Angelini Ventures Marks First Portfolio Company Exit as ResMed Acquires Noctrix Health for $340 million

Resmed Completes Acquisition of Noctrix Health, Expanding Clinical Sleep Health Portfolio

Resmed Announces Participation in the 46th Annual William Blair Growth Stock Conference

Resmed and ŌURA Partner to Expand Access to Sleep Health Education and Care

Search stocks

ResMed Inc. (RMD)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

ResMed Inc. (RMD)

Here Are Wednesday's Best Wall Street Analyst Research Calls: Block, Charles River Laboratories, Cognizant Technology, Constellation Energy, Credicorp, First Solar, GE Vernova, Huntsman, Macerich, and More

Why ResMed (RMD) is a Top Growth Stock for the Long-Term

ResMed: GLP-1 Threats Are Overstated

Is This the Right Time to Retain Resmed Stock in Your Portfolio?

Top 50 High-Quality Dividend Growth Stocks For June 2026

Angelini Ventures Marks First Portfolio Company Exit as ResMed Acquires Noctrix Health for $340 million

ResMed Inc. (RMD) Presents at 46th Annual William Blair Growth Stock Conference Prepared Remarks Transcript

Videolar

No Data

Press-relizlar

Angelini Ventures Marks First Portfolio Company Exit as ResMed Acquires Noctrix Health for $340 million

Resmed Completes Acquisition of Noctrix Health, Expanding Clinical Sleep Health Portfolio

Resmed Announces Participation in the 46th Annual William Blair Growth Stock Conference

Resmed and ŌURA Partner to Expand Access to Sleep Health Education and Care

Here Are Wednesday's Best Wall Street Analyst Research Calls: Block, Charles River Laboratories, Cognizant Technology, Constellation Energy, Credicorp, First Solar, GE Vernova, Huntsman, Macerich, and More

Why ResMed (RMD) is a Top Growth Stock for the Long-Term

ResMed: GLP-1 Threats Are Overstated

Is This the Right Time to Retain Resmed Stock in Your Portfolio?

Top 50 High-Quality Dividend Growth Stocks For June 2026

Angelini Ventures Marks First Portfolio Company Exit as ResMed Acquires Noctrix Health for $340 million

ResMed Inc. (RMD) Presents at 46th Annual William Blair Growth Stock Conference Prepared Remarks Transcript

Videolar

No Data

Press-relizlar

Angelini Ventures Marks First Portfolio Company Exit as ResMed Acquires Noctrix Health for $340 million

Resmed Completes Acquisition of Noctrix Health, Expanding Clinical Sleep Health Portfolio

Resmed Announces Participation in the 46th Annual William Blair Growth Stock Conference

Resmed and ŌURA Partner to Expand Access to Sleep Health Education and Care